AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02246478 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals~* Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals
Study NCT02658604 — intervention group
Intervention type: OTHER
Intervention: Home medication review by a pharmacist
Description: Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
Study NCT00418184 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phosphatidylserine-Omega3
Description: Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
Study NCT00418184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colored cellulose tainted with fishy odor
Description: as arm 1
Study NCT01870180 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeBag
Description: fabric bag of beads which can be heated in a microwave
Study NCT01870180 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00605930 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pyruvate, creatine, niacinamide
Description: A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
Study NCT00605930 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
Study NCT03022071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
Study NCT03022071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavior therapy
Description: In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
Study NCT00733330 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique
Description: Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
Study NCT00733330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation
Description: Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
Study NCT02465567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/9.6 μg
Description: Budensonide, Glycopyrronium, and Formoterol Fumarate
Study NCT02465567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFF MDI 14.4/9.6 μg
Description: Glycopyrronium, and Formoterol Fumarate
Study NCT02465567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGF MDI 160/14.4/9.6 μg
Description: Budensonide, Glycopyrronium, and Formoterol Fumarate
Study NCT02465567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFF MDI 320/9.6 μg
Description: Budensonide, and Formoterol Fumarate
Study NCT01247948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: navigation assisted spine surgery
Description: navigation assisted pedicle screw placement of spine surgery
Study NCT01247948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional spine surgery
Description: traditional spine surgery without navigation assist
Study NCT03965858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - low dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to low Esketamine dose.
Study NCT03965858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - medium dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to medium Esketamine dose.
Study NCT03965858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine DPI - high dose
Description: Esketamine DPI is to be administered via dry powder inhaler. Each dose correspond to high Esketamine dose.
Study NCT03965858 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo DPI is to be administered via dry powder inhaler.
Study NCT02480465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobelitazone 0.5mg
Description: Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
Study NCT02480465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
Study NCT00905125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone®
Description: Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
Study NCT00905125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix®
Description: Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
Study NCT04460105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Participants will receive 300 mg of lanadelumab IV infusion on Day 1 and Day 4.
Study NCT04460105 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo matching IV infusion on Day 1 and Day 4.
Study NCT02682602 — intervention group
Intervention type: DEVICE
Intervention: DePuy Synthes total hip arthroplasty
Study NCT02682602 — intervention group
Intervention type: RADIATION
Intervention: Computer tomography
Description: Computer tomography (CT) scan of the hip for creation of bone models.
Study NCT02682602 — intervention group
Intervention type: RADIATION
Intervention: Fluoroscopy surveillance
Description: Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
Study NCT02070185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 exposures arm
Description: During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 2 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period).
Study NCT02070185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 7 exposures arm
Description: During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).~During a 4-wk conditioning period, children were exposed either 7 times to each beverage.~After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period).
Study NCT02366949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1217389
Description: BAY1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 > (or equal to) a relative bioavailability assessment of BAY1217389 liquid capsule formulation compared to BAY1217389 oral solution will be performed.
Study NCT02366949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BAY1217389
Description: BAY1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).~After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.~In a higher dose level Cohort 4 > (or equal to) a relative bioavailability assessment of BAY1217389 liquid capsule formulation compared to BAY1217389 oral solution will be performed.
Study NCT02366949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be given once per week IV at 90 mg/m\^2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
Study NCT02366949 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be given once per week IV at 90 mg/m\^2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
Study NCT03476980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized to Umbilical Cord Milking at birth
Description: The subjects in this group were randomized to UCM X4 at birth. This procedure infuses a placental transfusion of blood by milking the umbilical cord towards the infant at birth.
Study NCT03476980 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Randomized to Delayed Cord Clamping at birth
Description: The subjects in this group were randomized to DCC at birth. At delivery, the obstetrician was instructed to delay clamping of the umbilical cord for 60 seconds.
Study NCT03190486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging (fMRI)
Description: During fMRI, healthy volunteers will listen 80 baby's cry.
Study NCT01223612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
Study NCT01223612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified ETDRS laser
Description: Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
Study NCT00515645 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head-down tilt and immersion
Description: Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
Study NCT03482440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salsalate Oral Tablet
Description: 1500mg twice daily for 5 days prior to experimental testing
Study NCT03482440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo oral table twice daily for 5 days prior to experimental testing
Study NCT03131180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Learning Healthcare System
Description: The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
Study NCT03977649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erenumab
Description: erenumab 140 mg sc every 4 weeks
Study NCT03977649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo sc every 4 weeks
Study NCT00536900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Advisor-Teller Money Manager
Description: The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
Study NCT00536900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FIT
Description: FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
Study NCT02997800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP >20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
Study NCT02997800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetalol
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Study NCT02997800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Study NCT02997800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saline infusion
Description: An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Study NCT02997800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline infusion
Description: An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
Study NCT02997800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 ml saline infusion
Description: Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
Study NCT01272336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acute Intermittent Hypoxia (AIH)
Description: Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
Study NCT01272336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM-Intermittent Room Air
Description: This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
Study NCT03732105 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Surgery-radiotherapy
Description: Patients in the surgery-radiotherapy group will receive Intensity Modulated Radiation Therapy (IMRT) at a dose of 50Gy/25fraction after randomization.
Study NCT03050632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: N-back
Description: The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
Study NCT03050632 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: White Bear Task
Description: For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
Study NCT01288664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVAGRAF
Description: Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
Study NCT02778919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLH-2109
Study NCT02778919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02778919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02778919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Leuprorelin acetate
Study NCT03083171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endotoxin
Description: At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
Study NCT03083171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
Study NCT03083171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.
Study NCT03083171 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrecizumab
Description: At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
Study NCT04630938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: intrathecal morphine will be added to anaesthetics
Study NCT04630938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine+lidocaine
Description: local anesthetic will be infused intravenously
Study NCT04630938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous saline infusion
Study NCT04433910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalesscent Plasma
Description: Transfusion